חומר רקע

Breath Diagnostic Technology This presentation was prepared by Scent Medical Technologies Ltd. (the “Company”), and is given to you only for the provision of concise information for the sake of convenience, and may not be copied or distributed to any other person. The data and information included in this presentation should not be interpreted as advice and should not be relied on for any purpose. Such data and information should not be copied or used except as expressly permitted in writing. This presentation does not purport to be comprehensive or to contain any and all information that might be relevant in connection with the making of a decision on an investment in securities of the Company nor Nextgen Biomed Ltd (“Nextgen”). No explicit or implicit representation or undertaking is given by any person regarding the accuracy or integrity of any information included in this presentation. No representation or undertaking is given regarding the realization or reasonableness of any forecasts regarding the future chances of the Company nor Nextgen. To obtain a wider picture of the activities of the Company and the risks entailed thereby, see the immediate reports of Nextgen concerning the Company’s recent activities and the Company’s ongoing merger with Nextgen, filed in the Israel Securities Authority and the Tel Aviv Stock Exchange Ltd. websites, including warnings regarding forward-looking information, as defined in the Securities Law, 5728- 1968, included therein. The forward-looking information in the presentation may not materialize, in whole or in part, or may materialize differently than expected, or may be affected by factors that cannot be assessed in advance. For the avoidance of doubt, it is clarified that neither the Company nor Nextgen undertakes to update and/or modify the information included in the presentation to reflect events and/or circumstances occurring after the date of preparation of the presentation. This presentation is not an offer nor invitation to buy or subscribe for any securities Nextgen and the Company. This presentation and anything contained herein are not a basis for any contract or undertaking and are not to be relied upon in such context. The information provided in the presentation is not a basis for the making of any investment decision, nor a recommendation or opinion, nor a substitute for the discretion of a potential investor. Forward Looking Statement Scentech Medical is a company specializing in Breath Test Diagnostics. It has been established on the infrastructure of several successful experiments over the last decade, including clinical trials, for the detection of infectious diseases, cancers, and other illnesses by a straightforward test of the patient's breath sample. Every living organism has unique metabolic processes that produce a particular signature. With the company’s exclusive technology and methodology for identifying "Volatile Organic Compounds" (VOCs) in exhaled breath, we can identify the direct compounds associated with the virus’s activity. Scentech Medical Knowledge and Experience Our technology detects the presence of unique metabolic processes that are associated with pathogens. Each pathogen has a different genetic expression, which creates a unique metabolic fingerprint. This enables our Rapid Scent Test (RST) to identify various diseases, even in the early stages of infection, when patients may be asymptomatic. IP Scentech Medical has a broad IP portfolio and trade secrets. Recently, the company filed a unique breakthrough patent for the detection of various types of cancer, tuberculosis (TB), and continuous monitoring of the effectiveness of the selected treatment for the disease. Developing a Digital Test Using Exhalation Technology for Rapid Virus Detection Pandemic Risks - We Discovered the World is not Safe Coronavirus Cases: 10,694,288 Deaths: 516,210 Estimated Expense: Over $2 Trillion * The displayed data is updated to 2/7/2020 • The world was not prepared • There is currently no vaccine • The virus is mutating, creating many new strains • Existing tests are expensive, inaccurate, and inefficient The COVID-19 pandemic exposed one of the main weaknesses of the 21st century’s globalization “worldwide pandemic risks” The Solution Biological Security in Borders The World Needs a Test that Offers Constant Updates Updates for virus mutations or new future viruses Speed Virus detection within seconds with on-the- spot results Accuracy Greater than 90% accurate Early Detection Detection of asymptomatic patients * All Pictures shown are for illustration purpose only Approximate Costs $150K - $400K per device $5-10 per test Approximate Dimensions Length: 1M / Width: 1.48M Device Operation: One operator with no technical skills required Approximate mapping in the next 6 weeks Approximate Outputs 840 tests per day (if operated 14 hours a day) Our Product: RBT – Rapid Breath Test Virus Breathalyzer: An efficient, accurate, real time Point of Care test Approximate Supply date October 2020 Scentech Medical will provide access for other breath test devices to the Scentech Medical Cloud Database of biomarkers and create a Great Network Effect Cloud Database of Metabolic “Fingerprints” https://www.youtube.com/watch?v=9rGian6PWqQ&feature=youtu.be Link to the video: Mapping stages of the virus’ “fingerprint” via clinical trials The company has started two clinical experiments in parallel and is planning another one soon to map the virus’s biomarkers. The mapping process is estimated to take six weeks Status Update Major Market Potential Borders – a potential charging $1 per test per passenger adds up quickly to $25 billion in market potential Public event location - charging 50 cents per test of patrons entering sports events or performances translates to more than a billion dollar market potential Medical centres -with the sale of dedicated devices at less than $1,000 per device to clinics and doctors worldwide, a potential market of over $8 billion will open up Estimated Roadmap Commercialization within 24 months Reverse merger into public company 3 1st prototype for Corona breathalyser First operational Corona breathalyser for identifying coronavirus in the field 18 Launch of 2nd generation breathalyser Define first coronavirus VOCs “Fingerprint” at Meir Medical Center 2 Post-marketing validation 4 12 24 1 -A Round Clinical Studies & Hardware Development: A+ Round B Round 5-7 6 month months months months months months months months months Validation Cross-section clinical trial with the Israeli Defense Forces JV establishment with a big medical devices company Scentech Medical in the Media https://www.ynet.co.il/articles/0,7340,L-5717024,00.html https://www.youtube.com/watch?v=EccjQtJXPxE&t=23s https://www.calcalist.co.il/markets/articles/0,7340,L-3807836,00.html https://www.globes.co.il/news/article.aspx?did=1001325335 http://www.israelnationalnews.com/News/Flash.aspx/496267 Link to the video: New development A Breathalyzer that detects whether you have the Coronavirus The Team Dr. Eliaz is Founder and Managing Director at Elrom Ventures. Rom was Managing Director and aMoon Fund, the Head of Merck ventures’ Fund and Bio-Incubator in Israel ,VP of Innovative Branded Products at Teva and CEO of NasVax (TASE: NSVX) and Immcure Therapeutics, VP of Product Development at, Intradigm (acquired by Silence Therapeutics), Rinat Neuroscience (acquired by Pfizer) and Alza (acquired by J&J).Rom received his PhD (cum- laude) chemical engineering and Biotechnology from the Weizmann Institute and Ben- Gurion University (BGU) and MBA from Harvard and Boston University joint program at BGU. Yaniv combines extensive financial expertise with significant experience in accelerating company growth. He was the Chief Strategy Officer at Excellence Investment House, where he managed over 35 billion dollars in assets. Yaniv is an NFX Alumnus and has an MA in Economics from Tel Aviv University. Dr. Rom Eliaz Executive Board Member Yaniv Chevron Chief Executive Officer Drew is a seasoned expert in the areas of metabolomics, breath analysis, and genetic expression diagnostics. He served on multiple advisory panels addressing the planning for pandemics and global health threats. He continues to be an outspoken advocate for the need for rapid diagnostic tools based on genetic expression, as a means to contain the spread of infectious diseases and improve health outcomes. Drew Morris Chief Research Officer Specialist in General and Urological Surgery In the past, he managed the organ transplant unit at Sheba Medical Center. He is a graduate of the FDA standard GMP examiners and was certified in Health Systems Management, at the Heller School, University of Brandeis, Boston, USA. Additionally, Dr. Cantor has served as the Head of Quality and Technology Administration in the USSR and as Head of the Technion Risk Management Training Village in Haifa. He founded and has served as the Head of the Medical Policy Division of the Medical Association in Israel. Dr. Amar earned her Ph.D. at the Faculty of Life Science, Bar- Ilan University, and completed post-doctoral studies at the Lautenberg Center for Immunology and Cancer Research at the Faculty of Medicine, Hebrew University, Jerusalem. Further, she holds a BSc and MSc from the Faculty of Biology at the Technion Israel Institute of Technology, as well as an MA in Law from Bar-Ilan University. Since graduating, she has held a number of management positions in the Biomed and Pharma Industries. Most recently, as CEO of ShizimXL medical devices accelerator and Chief of Business Development at Alvit Pharma. Regina brings her drive and passion for science to her role as the Analytical Laboratory Manager. She holds a PhD in Materials Chemistry from the University of Alberta and a BSc in Chemistry and Computer Science from Western University. Regina honed her analytical skills as a researcher at the Analytical Laboratory of the Israeli Air Force, where she specialized in the identification and method development for the analysis of non-metal materials used in the aviation industry. Dr. Keren-Or Amar Healthcare Business Consultant Dr. Regina Sinelnikov Analytical Lab Manager Dr. Udi Cantor Chief Medical Officer [email protected] / www.scentech-medical.com Thank you!